Who Owns Zentalis Pharmaceuticals Stock?
NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 50.88%
- Held by insiders
- 21.85%
- Institutional holders
- 154
- Institutions 50.9%
- Insiders 21.9%
- Public and other 27.3%
Who owns Zentalis Pharmaceuticals stock?
Institutional investors own about 50.9% of Zentalis Pharmaceuticals's shares, spread across 154 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 21.85% of ZNTL.
The largest institutional holders are 5AM Venture Management, LLC (5.51%), Blackrock Inc. (5.24%) and Squadron Capital Management LLC (5.16%). Together, the top 10 institutions control 37.2% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their ZNTL positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ZNTL
| Institution | Shares | % Held | Change |
|---|---|---|---|
| 5AM Venture Management, LLC | 3.95M | 5.51% | 0.0% |
| Blackrock Inc. | 3.75M | 5.24% | +195.6% |
| Squadron Capital Management LLC | 3.70M | 5.16% | +1.9% |
| Two Sigma Investments, LP | 3.02M | 4.22% | +2.3% |
| Vanguard Capital Management LLC | 2.84M | 3.96% | +22.7% |
| Acadian Asset Management. LLC | 2.68M | 3.74% | -5.8% |
| Citadel Advisors Llc | 2.30M | 3.21% | +32.7% |
| Renaissance Technologies, LLC | 1.61M | 2.25% | -17.0% |
| Opaleye Management Inc. | 1.41M | 1.97% | 0.0% |
| Orbimed Advisors LLC. | 1.39M | 1.94% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ZNTL
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.19M | 3.05% |
| iShares Trust-iShares Russell 2000 ETF | 1.22M | 1.70% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 676.40K | 0.94% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 575.85K | 0.80% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 574.77K | 0.80% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 545.84K | 0.76% |
| iShares Trust-iShares Russell 2000 Value ETF | 480.98K | 0.67% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Small-Cap Equity Fund | 320.46K | 0.45% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 243.65K | 0.34% |
| iShares Trust-iShares Micro-Cap ETF | 170.20K | 0.24% |
Frequently asked questions
Who is the largest shareholder of Zentalis Pharmaceuticals?
5AM Venture Management, LLC is the largest institutional shareholder of ZNTL, owning 5.51% of shares outstanding (3.95M shares) as of its latest 13F filing.
What percentage of Zentalis Pharmaceuticals is owned by institutions?
Institutions own about 50.9% of ZNTL shares and 65.1% of the public float.
How much of Zentalis Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 21.85% of ZNTL shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.